Annual Report of 2018

This year was very exciting for ETAP-Lab and we would like to share with you some of the 2018 major achievements:

  • A new atopic dermatitis model, the DNCB-induced model in Balb/c mice, has been developed with effective studies already in progress.
  • New studies for the account of TEMESIS have been performed showing remarkable effects of their lead TEM1657 drug candidate on Psoriasis and results have been presented in different congresses. Different formulations of their product remaining to be characterized.
  • Jean-François Bisson participated to the World Preclinical Congress in Lisbon to discuss chronobiology and animal welfare, a key point of our activity. Indeed, ETAP-Lab controls reverse light cycle and behavioral animal tests are run during their activity phases in order to have a thorough follow-up of the animal but also to monitor the possible side effects of a product.
  • ETAP-Lab has acquired new equipment including a C-Cube camera allowing to make reproducible pictures in very high quality, which is essential for the follow-up for the development of dermatological diseases.
  • ETAP-Lab established a collaboration with the European Institute of Antioxidants to measure total antioxidant capacities in skin tissue and fluids using PAOT© Technologies. Now, ETAP-Lab can pursue studies on antioxidant compounds administered locally or orally for other dermatological conditions such as vitiligo, extending further research possibilities.
  • A metagenomic project for the analysis of bacterial strains at the cutaneous level before (healthy mice) and after pathology induction (psoriasis, atopic dermatitis, skin inflammation) is in progress. 
  • Some projects and studies will be launched in 2019, including:

 → A preclinical study aiming at evaluating the efficacy of a miniaturized smart system built up to improve wound healing by light stimulation within the framework, the European project “MEDILIGHT”.

→ A study on skin explant models in animals for severe burns or long-term healing. Building the tests to evaluate explants’ parameters is planned for 2019.

  • Several new models are in progress and envisaged for 2019, including:

→ Atopic dermatitis mice model with mite induction, only available in Asia at the present time.

→ Vitiligo, acne, rosacea and alopecia mice models.


Through this year, ETAP-Lab has been able to prosper in the dermatology field with various projects, models and collaborations completed over the world. The main objective in 2019 is to develop new models/study methods to answer customer needs as well as future therapeutic issues. 

We are grateful for the trust that customers have placed in us to design and validate new models, as well as to carry out their pre-clinical studies. We are committed to always provide services of quality, rigor, ethical compliance, reactivity and are delighted to constantly evolve according to customer specific demands.

Annual Report of 2018